ASCO 2023 | Subgroup analysis of ATTRACTION-5: benefit of nivolumab in G/GEJ advanced + PD-L1-positive tumors

Masanori Terashima, MD, PhD, FACS, shares a sub-group analysis of the Phase III ATTRACTION-5 (NCT03006705) trial which evaluated the efficacy of nivolumab plus chemotherapy as postoperative adjuvant treatment for patients with pathological stage III gastric or gastroesophageal junction (G/GEJ) cancer who had undergone D2 or more extended gastrectomy. The trial did not meet its primary endpoint of of centrally-assessed relapse-free survival (RFS), however, the subgroup analysis revealed a benefit of the addition of nivolumab in patients with performance status 1 and stage IIIc, as well as those with PD-L1-positive tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.